Charles River Laboratories (CRL) Stock Forecast & Price Target
Charles River Laboratories · NYSE
$288.55-4.80 (-1.64%)
15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Charles River Laboratories, 10 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $175.00 to $310.00, a moderate spread. The average target of $249.58 sits 14% below the current $288.55. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.31 next quarter toward $12.69 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy1077%
Hold323%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to Charles River Laboratories.
As of Sep, 9 of 12 firms rate CRL a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRL EPS & revenue forecast
EPS · NEXT QUARTER
$3.31
Range $3.00 – $3.46 · 11 analysts · +39% YoY
Next period, 11 analysts expect Charles River Laboratories to earn $3.31 a share (range $3.00 – $3.46), versus $2.39 a year earlier. Full-year consensus is $11.32, growing to $12.69 the year after.
REVENUE · NEXT QUARTER
$952.7M
Range $943.0M – $974.1M · 11 analysts · -4% YoY
Revenue is expected to reach $952.7M (range $943.0M – $974.1M), -4.2% year-over-year. Full-year consensus is $3.9B, rising to $4.0B next year.
Top analysts covering Charles River Laboratories
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRL.
#1
Luke Sergott
Barclays · Rank #246
Buy
$300.00+4.0% to target
Overall win rate
40%
+ Follow
#2
Patrick Donnelly
Citigroup · Rank #344
Buy
$265.00-8.2% to target
Overall win rate
30%
+ Follow
#3
CW
Casey Woodring
JP Morgan
Buy
$310.00+7.4% to target
Coverage
—
+ Follow
#4
RM
Ross Muken
Evercore ISI Group
Buy
$300.00+4.0% to target
Coverage
—
+ Follow
#5
Ann Hynes
Mizuho
Hold
$230.00-20.3% to target
Coverage
—
+ Follow
CRL stock forecast FAQ
What is CRL's average 12-month price target?+
The 12 analysts with a live target average $249.58 for Charles River Laboratories over the next 12 months, ranging from a $310.00 high to a $175.00 low.
Is CRL stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 10 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRL?+
The Street-high target is $310.00 (JP Morgan), and the Street-low is $175.00 (UBS). The average of all 12 active targets is $249.58.
How many Wall Street analysts cover CRL?+
13 analysts have an active rating on Charles River Laboratories, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRL?+
Among analysts who currently cover CRL, Luke Sergott of Barclays has the strongest overall Quantellect track record (Rank #246). Their current call is Buy with a $300.00 target.
What is Charles River Laboratories's projected EPS for next quarter?+
The consensus estimate is $3.31 per share (range $3.00 – $3.46) across 11 analysts. Full-year EPS is projected at $11.32, rising to $12.69 the following year.
How much revenue is Charles River Laboratories expected to report next quarter?+
Consensus revenue is $952.7M (range $943.0M – $974.1M). Full-year revenue is projected at $3.9B, growing to $4.0B next year.
Have analysts been upgrading or downgrading CRL lately?+
As of Sep, 9 of 12 firms rate CRL a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
